USAID and DHFL Sign $10 million Loan Guarantee to Improve Healthcare in Urban India

IMT News Desk
IMT News Desk
· 3 min read
USAID

The U.S. Agency for International Development (USAID) and the Dewan Housing Finance Corporation Limited (DHFL) today officially announced the signing of a $10-million loan portfolio guarantee in an effort to improve access to capital for healthcare providers in Tier II & Tier III cities. Through the risk-sharing agreement signed between USAID and DHFL, the Mumbai-based lender will be able to provide up to $10 million to small- and medium-sized enterprises operating in the health sector in India, prioritizing lending to women entrepreneurs. Through this partnership, USAID and DHFL intend to achieve the following:

  • Increase outreach to de-risk and improve access to finance for the Indian healthcare sector, especially breaking barriers for women entrepreneurs so they can establish or expand their healthcare enterprises and services, buy equipment to improve diagnosis and treatment in their communities, and improve the viability of their enterprises;
  • Deepen collaboration with various borrowers throughout India, especially in Rajasthan, Odisha, Madhya Pradesh, and Chhattisgarh; and
  • Ensure improved access to quality, affordable healthcare and better health outcomes for underserved communities.

Speaking at the launch of the partnership, U.S. Consul General in Mumbai Edgard Kagan said, “The USAID-DHFL partnership will boost women’s empowerment by prioritizing them for lending, helping women access loans and expand and improve the viability of their businesses.  I am confident this partnership will take us one step closer to achieving the shared vision of improving health outcomes for underserved populations.”

Mr. Harshil Mehta, Joint Managing Director and CEO, DHFL, added: “DHFL’s relationship with USAID is a culmination of joint efforts to improve healthcare facilities across the country. It gives us an opportunity to help develop quality healthcare across India by offering convenient and customized financial solutions, especially for medical practitioners through medical equipment finance and expansion of facilities. DHFL has been undertaking extensive activities at grassroots level for the urban poor and those at the bottom of the pyramid, touching the lives of over millions of people through social programs and its excellent network across 349 locations.”

The partnership will take off with technical assistance provided by USAID’s flagship “Partnerships for Affordable Healthcare Access and Longevity” (PAHAL) program, implemented by IPE Global, a leading development sector consulting firm in South Asia.

L.M. Singh, Project Director & Head of Impact Investments at PAHAL, said, “The PAHAL project is proud to be at the center of this unique and powerful partnership. PAHAL, through its network of providers, is already reaching 10 million urban poor across seven high priority states, and we believe this partnership will ensure access to better technology, expanded service offerings, and reach for inclusive healthcare small and medium enterprises, thereby ensuring quality affordable care for the underserved.”

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk